For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Tirzepatide

Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)

Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Real-time market data

Pricing for Tirzepatide

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$6.89/mg

range $0.00–$93.33/mg

Sellers

73

from $0.00

45-day trend

+25.5%

vs 45-day avg $/mg

68 of 73 sellers have a current price· 48 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Tirzepatide

379 third-party tests across 41 vendors. Each card links to the full report.

All 379 COAs for Tirzepatide →
Measured purity 82.3%–100.0% across 248 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.91 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ20-14

Aggregated · 3rd-party listing
99.22 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by Aspire Peptides· batch TR10-032026-1

Aggregated · 3rd-party listing
99.81 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by Aspire Peptides· batch TR15-032026-1

Aggregated · 3rd-party listing
99.68 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by Orbitrex Peptides· batch 2G30726

Aggregated · 3rd-party listing
99.95 %
Jun 2026
Freedom Diagnostics Moderate

For

Tirzepatide

by Ion Peptide· batch ION2T20-06242026

Aggregated · 3rd-party listing
99.89 %
Jun 2026
Freedom Diagnostics Moderate

For

Tirzepatide

by Profound Aminos· batch Clear Cap/Bronze Crimp

✓ Vendor-published
99.11 %
Jun 2026
TrustPointe Analytics Moderate

For

Tirzepatide

by Peptide Partners· batch SPL-4130

COA on file
Aggregated · 3rd-party listing
99.88 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ30-13

Aggregated · 3rd-party listing
99.82 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by Peptide Plugs· batch 005-B-SM

Aggregated · 3rd-party listing
99.90 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ60-04

Aggregated · 3rd-party listing
99.03 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by Voltera Sciences· batch TR60.05.28.26

Aggregated · 3rd-party listing
99.77 %
Jun 2026
Janoshik Analytical Limited

For

Tirzepatide

by EZ Peptides· batch EZP-2P2005162026-04

✓ Vendor-published
99.77 %
Jun 2026
Janoshik Analytical Limited

For

Tirzepatide

by EZ Peptides· batch EZP-2P2005162026-04

COA on file
Aggregated · 3rd-party listing
99.77 %
May 2026
Janoshik Analytical Limited

For

Tirzepatide

by EZ Peptides· batch EZP-2P3004212026-03

✓ Vendor-published
99.80 %
May 2026
Janoshik Analytical Limited

For

Tirzepatide

by EZ Peptides· batch EZP-2P3004212026-03

COA on file
✓ Vendor-published
99.96 %
May 2026
Kovera Labs

For

Tirzeppatide

by Reta One Labs· batch TR300626

COA on file
Aggregated · 3rd-party listing
99.29 %
May 2026
Horizon Analytical

For

Tirzepatide

by Pepsgpt· batch P-9887337-P

Aggregated · 3rd-party listing
99.85 %
May 2026
Kovera Labs

For

Tirzepatide

by Glacier Aminos· batch TIR20GA-04

Aggregated · 3rd-party listing
99.93 %
May 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ40-14

Aggregated · 3rd-party listing
99.92 %
May 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ20-13

Aggregated · 3rd-party listing
99.89 %
May 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ30-12

Aggregated · 3rd-party listing
99.93 %
May 2026
ILS Labs Strong

For

Tirzepatide

by Ion Peptide· batch ION2T60-05042026

Aggregated · 3rd-party listing
99.90 %
May 2026
Analytical Formulations, Inc.

For

Tirzepatide

by Alpha Peptides· batch T60-42326428

Aggregated · 3rd-party listing
99.87 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Tirzepatide

by Skye Peptides· batch TZ26-60-003

Research depth

23 citations indexed for Tirzepatide

All research on Tirzepatide →

Study · 2026

Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study

Objective To compare the real-world weight loss effectiveness and safety of tirzepatide and semaglutide in patients treated for obesity, including those with prior obesity medication (OM) use.

review · 2026

Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation

Introduction Metabolic diseases, including type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and obstructive sleep apnoea (OSA), are characterized by a complex and interconnected pathophysiological syndrome.

case-report · 2026

Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman

BACKGROUND Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes and chronic weight management in adults meeting clinical criteria. Appetite suppression and gastrointestinal intolerance can markedly reduce intake.

Study · 2026

Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan

Background Tirzepatide, a multi-agonist incretin agent that targets body weight and metabolic parameters, has stronger weight reduction and glycemic control effects than existing agents.

Study · 2026

Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells

Study · 2026

Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with significant cardiometabolic and hepatic risks.